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Cell surface processing of the P1 
adhesin of Mycoplasma pneumoniae 
identifies novel domains that bind 
host molecules
Michael Widjaja1, Iain James Berry1, Veronica Maria Jarocki1, Matthew paul padula3, 
Roger Dumke2,4 & Steven Philip Djordjevic1,3,4*
Mycoplasma pneumoniae is a genome reduced pathogen and causative agent of community 
acquired pneumonia. The major cellular adhesin, P1, localises to the tip of the attachment organelle 
forming a complex with P40 and P90, two cleavage fragments derived by processing Mpn142, and 
other molecules with adhesive and mobility functions. LC-MS/MS analysis of M. pneumoniae M129 
proteins derived from whole cell lysates and eluents from affinity matrices coupled with chemically 
diverse host molecules identified 22 proteoforms of P1. Terminomics was used to characterise 
17 cleavage events many of which were independently verified by the identification of semi-
tryptic peptides in our proteome studies and by immunoblotting. One cleavage event released 
1597tSAAKpGApRppVppKpGApKppVQppKKpA1627 from the C-terminus of P1 and this peptide was 
shown to bind to a range of host molecules. A smaller synthetic peptide comprising the C-terminal 
15 amino acids, 1613pGApKppVQppKKpA1627, selectively bound cytoskeletal intermediate filament 
proteins cytokeratin 7, cytokeratin 8, cytokeratin 18, and vimentin from a native A549 cell lysate. 
Collectively, our data suggests that ectodomain shedding occurs on the surface of M. pneumoniae where 
it may alter the functional diversity of P1, Mpn142 and other surface proteins such as elongation factor 
Tu via a mechanism similar to that described in Mycoplasma hyopneumoniae.
The attachment organelle is a structurally and functionally sophisticated component of the M. pneumoniae cell 
that is responsible for the assembly of proteins essential for motility and adherence1–8. An extensive list of host 
molecules including fibronectin9–13, fibrinogen10–14, plasminogen11–13,15–17, lactoferrin10–12, laminin10–12, and vit-
ronectin10–13 interact with surface accessible adhesins in M. pneumoniae. Other less well-defined host molecules 
include sialylated molecules18, oligosaccharides19, glycolipids20, and glycoproteins21.
The gene mpn141 encoding the major adhesin P1 is located in the same operon along with mpn140 and 
mpn142 and these three genes constitute a polycistronic transcriptional unit22,23. mpn140 encodes for a 
28 kDa putative phosphoesterase24 and while it has been shown to degrade nanoRNA and dephosphorylate 
3′-phosphoadenosine 5′-phosphate to AMP25, no role in adherence has been assigned for this protein. mpn142 
generates a 130 kDa product (Mpn142) that is cleaved into two fragments of 40 kDa (P40) and 90 kDa (P90) 
immediately after or concurrent with translation26,27. The cleavage event in Mpn142, first described over 25 years 
ago, was the first in what is now known to be a highly processed molecule on the surface of M. pneumoniae28. P1 
is a remarkably versatile molecule and the subject of numerous studies over the past 30 years. The only cleavage 
event that has been accurately assigned to P1 is the removal of the N-terminal 59 amino acids as a leader pep-
tide29. Molecular cross-linking and immunogold-labelling studies indicated that P1 forms a complex with P30, 
P40, and P9030,31 that colocalise to the tip of the attachment organelle to act in concert to effect different func-
tions5,6,23,32. Cross-linking studies with paraformaldehyde identified P1 complexes containing Mpn309 (P65), 
Mpn272 (DnaK), C-terminal truncated forms of DnaK and P1, pyruvate dehydrogenase α subunit (Pdh-A), and 
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high molecular weight proteins 1 (HMW1) and 3 (HMW3)33. Anti-P1 antibodies reduce adherence of M. pneu-
moniae to abiotic and host cell surfaces3,34–38 and M. pneumoniae P1 mutants are also unable to adhere35,36,39–41. 
For P1 to translocate to the surface, localise correctly within the attachment organelle and to maintain stability, 
interactions with accessory proteins P40, P90, HMW1, and TopJ are required2,42–46. C-terminal regions of P1 have 
featured in various recombinant vaccines that seek to control infections caused by M. pneumoniae.
The P1 adhesin is highly immunogenic and is often detected by sera from M. pneumoniae-infected 
patients36,47,48. Several studies have shown that the carboxyl half of P1 is highly immunogenic and crucial for 
its function as an adhesin37,49–55. To identify regions within P1 that are recognised by the host humoral immune 
response, Schurwanz et al. generated 15 recombinant fragments spanning the P1 molecule and exposed them 
to the serum of patients with M. pneumoniae infections55. Three recombinant fragments within P1, one in the 
N-terminus and two spanning C-terminal regions, were strongly immunoreactive with sera from greater than 
90% of the patients55. Guinea pig antibodies generated to one of the C-terminal regions significantly reduced 
binding of M. pneumoniae to HBEC (primary bronchial epithelial), MRC-5 (fetal lung fibroblasts), and HeLa 
(cervical carcinoma) cell lines55. These data informed the creation of a chimeric recombinant protein which 
included this carboxyl region of P1 and a region in the P30 adhesin. Antibodies raised against this chimeric 
protein reduced M. pneumoniae adherence to human bronchial epithelial cells by more than 95%55, and also 
successfully reduced M. pneumoniae colonisation in animal models56.
Here we sought to determine if P1 is processed on the surface of M. pneumoniae. Tryptic peptides that mapped 
to different regions within P1 were frequently encountered when characterising size-fractionated eluents gen-
erated during affinity chromatography using different host molecules as bait. These peptides were mapped to 
the P1 molecule providing insight into the complex processing events that target this molecule. Precise cleavage 
sites were determined using an N-terminome approach57 and by mapping semi-tryptic peptides identified from 
our proteome studies. Naturally occurring cleavage fragments of P1 were identified by LC-MS/MS analysis i) 
because they bound to affinity resins loaded with host proteins, ii) by mapping tryptic peptides derived from 
proteins spots from 2D-SDS PAGE, and iii) by immunoblotting studies using serum raised against fifteen differ-
ent regions of P1. These independently acquired, but complementary datasets enabled a rigorous assessment of 
cleavage events in the P1 adhesin. Finally, microtitre binding assays and microscale thermophoresis showed that 
the C-terminus of P1 binds various host molecules.
Methods and Materials
Strains. M. pneumoniae (M129 strain, ATCC 29342) cells were cultured as described previously58. Cells were 
grown in modified Hayflick’s medium in tissue culture flasks at 37 °C. Human lung carcinoma (A549, ATCC 
CCL-185) cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with 10% heat inactivated fetal 
bovine serum. Cells were grown in tissue culture flasks at 37 °C with 5% CO2.
Cell preparation for one dimensional- and two dimensional-SDS polyacrylamide gel electro-
phoresis. M. pneumoniae cells were harvested as described previously59. In brief, cells were lysed with son-
ication in 7 M urea, 2 M thiourea, 40 mM Tris-HCl, and 1% (w/v) C7BzO detergent (Sigma) after washing with 
PBS. Proteins were reduced and alkylated with 5 mM tributylphosphine and 20 mM acrylamide monomers before 
precipitation with acetone. Protein was resuspended in 7 M urea, 2 M thiourea, and 1% (w/v) C7BzO for 1D- and 
2D-SDS PAGE.
Gel electrophoresis was performed as described previously60,61. Approximately 80 µg and 250 µg of protein was 
used for 1D- and 2D-SDS PAGE, respectively. Gels were fixed and stained by either Flamingo fluorescent gel stain 
(Bio-Rad) or Coomassie Blue G-250 (Sigma).
In-gel trypsin digestion was performed as described previously62 for mass spectrometry analysis. Gel pieces 
were excised, destained, dehydrated, and then incubated with trypsin Gold MS grade (Promega) in 100 mM 
NH4HCO3. Tryptic peptides were extracted by sonication and stored in 4 °C until needed for mass spectrometry.
Liquid chromatography tandem mass spectrometry (LC-MS/MS) and data analysis. LC-MS/
MS was performed as described previously61. In brief, 5 μg of peptides in 15 μl was loaded into an Eksigent AS-1 
autosampler connected to a Tempo nanoLC system (Eksigent, Livermore, CA, USA) and washed onto a PicoFrit 
column (75 μm × 150 mm) packed with Magic C18AQ resin (Michrom Biosciences, CA). Peptides were eluted 
from the column into the source of a QSTAR Elite hybrid quadrupole-time-of-flight mass spectrometer (Sciex, 
Redwood, CA, USA).
Files generated from LC-MS/MS were searched against the MSPnr100 database63 with the following param-
eters: Fixed modifications: none; Variable modifications: propionamide, oxidized methionine, deamidation; 
Enzyme: semi-trypsin; Number of allowed missed cleavages: 3; Peptide mass tolerance: 100 ppm; MS/MS mass 
tolerance: 0.2 Da; and Charge state: 2+, 3+, and 4+. For samples collected from the ‘Surface proteome analysis 
of M. pneumoniae (Biotinylation)’ and ‘Affinity chromatography host binding M. pneumoniae complexes (A549)’ 
listed below, variable modifications also included NHS-LC-Biotin (K) and NHS-LC-Biotin (N-term). ‘Affinity 
chromatography host binding M. pneumoniae complexes (A549)’ was also searched against ‘homo sapiens’ entries 
in MSPnr100 to identify biotinylated surface A549 proteins.
Surface proteome analysis of M. pneumoniae. Biotinylation of the M. pneumoniae cells was performed 
as described previously28. The biotinylation reaction was allowed to proceed for 30 seconds on ice. Biotinylated 
surface proteins were confirmed with western blots using ExtrAvidin-HRP (Sigma).
Trypsin shaving of M. pneumoniae cells was carried out as described previously12. Shaving was for 5 minutes at 
37 °C and released peptides were trypsin digested a second time before analysis by LC-MS/MS.
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Affinity chromatography of host binding M. pneumoniae complexes. ‘Bait’ host proteins used 
for affinity chromatography include fibronectin (Code: 341635) and plasminogen (Code: 528175) from human 
plasma supplied by Merck Millipore. Bovine actin (Code: A3653) and fetuin (Code: F3004) was supplied by 
Sigma.
Affinity chromatography using host proteins bound to Avidin Agarose (Pierce) as ‘Bait’ was performed as 
described previously28. M. pneumoniae cells were lysed in 1% (w/v) C7BzO (Sigma-Aldrich) in PBS (pH 7.8) 
to obtain native complexes. The native complex cell lysate was incubated with host proteins bound to Avidin 
Agarose (‘Bait’). This mixture was washed with PBS and host protein binding complexes (‘Prey’) were eluted 7 M 
urea, 2 M thiourea, 40 mM Tris-HCl, and 1% (w/v) C7BzO. Elutions were separated by 1D-SDS PAGE and pro-
teins were identified by LC-MS/MS as described above.
Affinity chromatography using human lung carcinoma (A549) surface proteins as ‘Bait’ was performed as 
described previously28. A549 cells were biotinylated, lysed, and bound to Avidin Agarose (‘Bait’). As above, this 
mixture was incubated with native M. pneumoniae complexes followed by washes and eluents to obtain a fraction 
of A549 binding complexes (‘Prey’).
Affinity chromatography using heparin HiTrap columns (GE Healthcare) was performed as described pre-
viously28. M. pneumoniae cells were lysed in 10 mM sodium phosphate, 0.1% Triton TX-100 (pH 7.0) to obtain 
native complexes. Approximately 300 µg of soluble complexes was loaded onto a HiTrap Heparin HP column (GE 
Healthcare). The column was washed with 10 mM sodium phosphate (pH 7.0) and heparin binding complexes 
were sequentially eluted in increasing concentrations of sodium chloride (pH 7.0).
Dimethyl labelling of M. pneumoniae and LC-MS/MS analysis. Dimethyl labelling of M. pneumo-
niae proteins was carried out as described previously28,64. 1 mg of M. pneumoniae protein was labelled in 40 mM 
formaldehyde (Ultrapure grade, Polysciences), 20 mM sodium cyanoborohydride, 100 mM Hepes (pH 6.7) for 
4 hours at 37 °C. The reaction was quenched with 100 mM ammonium bicarbonate, precipitated in acetone:meth-
anol (8:1), and digested with trypsin.
Peptides were analysed using both the Sciex 5600 and Thermo Scientific Q Exactive™ mass spectrometers. The 
methods, protocols, and parameters used have been described previously28.
Bioinformatic analysis of the P1 adhesin. Bioinformatic predictions and analysis was performed 
as described previously28. The bioinformatic tools used were: ProtParam65, TMpred66, PONDR® (VSL2 pre-
dictor)67, and ScanProsite68. Predicted glycosaminoglycan binding motifs searched in ScanProsite included 
binding sites for heparin (X-[HRK]-[HRK]-X-[HRK]-X motif )69, heparin sulfate (X-[HRK]-X-[HRK]-
[HRK]-X)70, or clusters of basic amino acid residues (X-[HRK]-X(0,2)-[HRK]-X(0,2)-[HRK]-X and 
X-[HRK]-X(1,3)-[HRK]-X(1,3)-[HRK]-X).
Immunoblot of M. pneumoniae cell lysates using Anti-P1 serum. 60 µg of M. pneumoniae cell lysate 
proteins were separated on 1D-SDS PAGE as described above. Proteins were transferred to PVDF (polyvinylidene 
fluoride) membranes using a semidry method71. Membranes were blocked with 5% (w/v) skim milk powder in 
PBS, and 0.1% (v/v) Tween 20 (PBS-Tween) for 1 hour at 25 °C. Membranes were cut in to individual lanes and 
then separately probed with guinea pig sera raised against different regions of the P1 adhesin (guinea pig sera 
was generated in a previous study55) for 1.5 hours at 25 °C in PBS-Tween. Membranes were washed three times 
over 30 minutes before being probed a second time in peroxidase-conjugated anti-guinea pig antibodies (1:3000, 
Sigma) for 1 hour at 25 °C in PBS-Tween. Membranes were washed again three times over 30 minutes and devel-
oped with DAB tablets (3,3′-Diaminobenzidine, Sigma).
Binding of P1 C-terminus to human proteins in ELISA. Human proteins used for ELISA include: 
plasma fibrinogen (Code: F3879), plasma fibronectin (Code: 11051407001), Glu-plasminogen (Code: P7999), 
vitronectin (Code: SRP3186), laminin (Code: L6274), and lactoferrin (Code: L1294) which were all supplied by 
Sigma.
Binding affinity measured by ELISA was performed as described previously17. Recombinant protein 
RP15 was produced as described55 and both C-terminal peptides were synthesised by Chempeptide Limited 
(China). P1-30 (1597TSAAKPGAPRPPVPPKPGAPKPPVQPPKKPA1627) without any tags, but P1-15 
(1613PGAPKPPVQPPKKPA1627) was sequenced with an N-terminal biotin tag.
15 µg/ml of C-terminal P1 fragments were bound to wells and incubated with different host proteins. Wells 
were then incubated with different antiserum raised against the different host proteins at the following dilutions 
(all from Sigma): anti-fibrinogen 1:3000, anti-fibronectin 1:1000, anti-plasminogen: 1:2500, anti-vitronectin 
1:5000, anti-laminin 1:750, and anti-lactoferrin 1:5,000. These incubations were followed by incubations with 
anti-rabbit IgG (Dako) or anti-goat IgG (both 1:2,000). Detection was measured by adding Tetramethylbenzidine 
(Sigma) followed by 1 M HCl, and absorbance was measured at 450 nm (620 nm as reference).
Binding of the P1 C-terminus to A549 human lung cells. Freshly grown A549 cells were immobilised 
in 96-well microtitre plates as described in17. Immobilised A549 cells were incubated with 10 µg/ml of either 
RP15, P1-30, or P1-15 and binding affinity was measured with antiserum raised against RP15 (1:100) as described 
above. Absorbance detection at 450 nm is the same as described above.
Affinity chromatography of complexes that bind the P1 C-terminus. The C-terminal sequence of 
P1 (P1-15) was synthesised with an N-terminal biotin tag by Chempeptide Limited (China). Affinity chromatog-
raphy was performed similar to the section above. In brief, 1 mg of the peptide was added to Avidin Agarose beads 
for 16 h at 4 °C. The beads were washed four times (5 ml per wash) with PBS before being incubated with native 
A549 cell lysates (harvested in 1% w/v C7BzO in PBS) for 16 h at 4 °C. Non-binding proteins were washed from 
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Figure 1. Cleavage map of the P1 adhesin. The full length proteoform (1627 amino acids) is shown as the black 
bar with cleavage sites above and fragments below this bar. Cleavage sites identified from dimethyl labelling and 
semi-tryptic sites are shown as the blue and red arrows, respectively. Sequences where these cleavage sites occur 
are also shown. Putative heparin binding sites (Hep, blue boxes, motif: X-[HRK]-[HRK]-X-[HRK]-X), heparan 
sulfate binding sites (HepS, blue boxes, motif: X-[HRK]-X-[HRK]-[HRK]-X), clusters of basic residues (HepB, 
blue boxes, motifs: X-[HRK]-X(0,2)-[HRK]-X(0,2)-[HRK]-X or X-[HRK]-X(1,3)-[HRK]-X(1,3)-[HRK]-X), 
and transmembrane domains (TmD, yellow boxes, TmD1 predicted by TMpred66, TmD2 previously predicted32, 
TmD3 previously predicted36, and TmD4 previously predicted in a P1 paralog73) are shown within the black 
bar. Putative transmembrane domains and the location of 15 subregions of P1 (grey ‘RP’ boxes) expressed as 
recombinant proteins from an earlier study55 are shown. Predicted disordered regions appear as purple boxes 
in the grey bar. Acidic and basic regions within P1 are identified as yellow and blue bars, respectively. Peptides 
released from surface shaving experiments and identified by mass spectrometry are shown in the light green 
boxes within the grey bar. Grey bars represent fragments of P1 identified during SDS-PAGE of whole cell 
lysates. Red bars represent fragments of P1 recovered from lysates of M. pneumoniae that have their surface 
proteins labelled with biotin (surface exposed fragments of P1). Peptides identified by mass spectrometry of P1 
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the column with four washes (5 ml per wash) of PBS and protein complexes with an affinity to the peptide were 
eluted from the column with 7 M urea, 2 M thiourea, 40 mM Tris-HCl, and 1% (w/v) C7BzO (4 times of 2 ml). 
Eluents were concentrated with a Macrosep® 3 kDa cutoff centrifugal device (Pall), precipitated with acetone, and 
separated by 1D-SDS PAGE. The whole lane was divided into sections, in-gel digested with trypsin, and analysed 
by LC-MS/MS as described above.
Microscale thermophoresis of P1-15 binding affinity. Binding affinities to fluorescent labelled host 
proteins was measured by microscale thermophoresis as described in72. Microscale thermophoresis was set to 30 s 
and samples were scanned with 40%, 60% and 80% MST Power. Dissociation constants were determined from 
generated dissociation curves with set hot/cold or thermophoresis settings. As a control, a scrambled version of 
the C-terminal P1 peptide (PKPPRAAPPKAPTPVPPGPASPVKKPKQAPG) was synthesised by Chempeptide 
Limited (China) without any tags and binding affinities was measured.
Ethical approval. Guinea pig sera used in this study was generated in a previous study55. The animal exper-
iments in that previous study were proved by the ethical board of Landesdirektion Sachsen, Dresden, Germany 
(no. 24-9168.25-1).
Results
Bioinformatic analysis of the P1 adhesin. The P1 adhesin has a predicted mass of 176.3 kDa and a pI 
of 8.53 and contains six predicted transmembrane regions and nine putative glycosaminoglycan binding sites 
(Fig. 1). The first transmembrane region (spanning the N-terminus), and the last transmembrane region (span-
ning the C-terminus) have been identified in previous studies of P132,36,66, and a P1 paralog of Mycoplasma geni-
talium73. The glycosaminoglycan binding sites consist of reiterated copies of positively charged amino acids that 
are likely to be important in interactions with sulphated derivatives of heparin and heparan sulfate. Analysis of P1 
using PONDR® identified seven putative disordered regions that span at least 30 amino acids (Fig. 1). Modules in 
P1 enriched in acidic (E, K) and basic (K, R, H) amino acids were identified. Disordered region and protein mod-
ules enriched in acidic and basic amino acids have been described in adhesin families in the respiratory pathogen 
M. hyopneumoniae and these were influential in the location of a subset of important cleavage sites60–62,74. We 
confirmed the precise location of 17 cleavage sites in P1 (shown below), 11 of which reside in predicted regions of 
disorder (Fig. 1). Cleavage sites did not seem to be over-represented in acidic or basic domains.
The P1 adhesin is processed extensively on the M. pneumoniae cell surface. P1 peptides identi-
fied by LC-MS/MS analyses of size fractionated M. pneumoniae lysates identified 23 proteoforms ranging in size 
from 17 to 176 kDa including the full length proteoform without the N-terminal signal sequence (Fig. 1). The 
full length and an additional 16 smaller proteoforms of P1 were identified by LC-MS/MS of size fractionated cell 
lysates separated by SDS-PAGE (grey bars; Fig. 1). The migration behaviour of these 17 proteoforms of P1 was 
consistent with masses predicted by ProtParam65. Trypsin shaving of the M. pneumoniae cell surface released 
trypsin accessible peptides (green boxes within a grey bar in Fig. 1) that span most of the adhesin indicating that 
P1 is exposed on the cell surface. This was consistent with LC-MS/MS analysis of size-fractionated biotinylated 
proteins that were first enriched using avidin chromatography which identified 14 proteoforms (full and frag-
ments 2, 3, 5, 7, 10, 11, 13, 14, 16, 17, 20, 21, and 22) of P1 (red bars in Fig. 1). These data suggest that cleaved P1 
proteoforms are surface accessible.
Several other proteoforms of P1 were identified by LC-MS/MS of protein bands digested in-gel from affinity 
experiments. Two proteoforms of P1 with masses of 149 kDa (fragment 1) and 101 kDa (fragment 3) (orange bars 
in Fig. 1) were identified from columns coupled with biotinylated A549 surface protein complexes suggesting that 
large P1 proteoforms with multiple binding domains are required to bind surface receptors on A549 cells. Eluents 
derived from columns coupled with fetuin and actin were particularly useful for identifying the full length protein 
and fragments 1, 2, 4, 7, 8, 10, 11, 16 and 18 of P1. Nine fragments (1, 2, 4, 7, 8, 10, 11, 16, and 18; yellow bars in 
Fig. 1) were recovered from columns coupled with fetuin, and six fragments (1, 4, 7, 8, 10, and 16; light blue bars 
in Fig. 1) were recovered from columns coupled with actin. Six fragments (2, 5, 12, 13, 14, 18) were identified 
from columns coupled with plasminogen (purple bars in Fig. 1). For the eleven fragments identified from heparin 
chromatography (blue bars in Fig. 1; fragments: 2, 4, 5, 6, 7, 9, 10, 12, 14, 15, and 16), only two (fragment 14 and 
16) did not contain any of the predicted glycosaminoglycan binding motifs identified with ScanProsite. Fifteen 
fragments (2, 4, 5, 6, 7, 9, 11, 13, 14, 16, 17, 18, 19, 20, and 21) were identified in eluents from columns coupled 
with fibronectin (green bars in Fig. 1).
A global M. pneumoniae dimethyl labelling approach was used to identify internal neo-N termini. Ten cleav-
age sites were identified in P1 using this approach (Table 1, blue arrows in Fig. 1). Semi-tryptic peptides, defined 
as peptides with only one tryptic end (Table 1, red arrows in Fig. 1) were also identified, implying seven additional 
cleavage sites in P1. Four distinct sites in P1 showed evidence that surface accessible amino-peptidases may alter 
neo-N-termini (Fig. 1 and Table 1): 162NPF↓G↓GF↓G↓LS↓GAA173 (cleavage site 2), 767NQK↓L↓T↓VAP↓TQG777 
(cleavage site 8), 1148TQR↓AL↓I↓W↓A↓PRP1158 (cleavage site 12), and 1558AGF↓A↓L↓S↓NQK1566 (cleavage site 
16) in a manner that is similar to amino-peptidase processing events reported in the major adhesin families in M. 
hyopneumoniae57,64,74,75. A large predicted disorder region spanning 196 amino acids near the carboxyl terminal 
fragments isolated from affinity chromatography of fetuin (yellow bars), actin (light blue bars), A549 surface 
protein complexes (orange bars), fibronectin (green bars), heparin (blue bars), and plasminogen (purple bars) 
are shown.
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No. ID Peptide Sequence Score E-value
N-terminal dimethyl labelled peptides
1 N1 R.73NTSFSSLPLTGENPGAWALVR93.D 107 6.20E-09
N2 T.75SFSSLPLTGENPGAWALVR93.D 26 0.039
3 N3 R.224TESGQNTSTTGAMFGLKVKNAEADTAKSNEKLQGAEATGSSTTSGSGQSTQR275.G 72 6.60E-07
5 N4 K.398AMTANYPPSWR408.T 67 5.70E-05
6 N5 R.574MAVAGAKFVGR584.E 62 5.00E-04
8 N6 K.770LTVAPTQGTNWSHFSPTLSR789.F 121 7.00E-11
N7 L.771TVAPTQGTNWSHFSPTLSR789.F 77 8.10E-07
N8 T.772VAPTQGTNWSHFSPTLSR789.F 64 1.00E-05
N9 P.775TQGTNWSHFSPTLSR789.F 35 5.30E-03
10 N10 T.1036KLNLPAYGEVNGLLNPALVETYFGNTR1062.A 173 7.10E-16
11 N11 W.1121LVTFTDFVKPR1131.A 58 7.20E-05
N12 T.1124FTDFVKPR1131.A 40 5.70E-03
12 N13 R.1151ALIWAPRPWAAFR1163.G 36 1.20E-03
N14 I.1154WAPRPWAAFR1163.G 27 2.10E-03
16 N15 F.1561ALSNQKVDVLTKAVGSVFKEIINR1584.T 160 1.70E-14
N16 A.1562LSNQKVDVLTKAVGSVFKEIINR1584.T 158 1.30E-13
N17 L.1563SLSNQKVDVLTKAVGSVFKEIINR1584.T 184 3.90E-16
N18 S.1564NQKVDVLTKAVGSVFKEIINR1584.T 102 4.60E-09
17 N19 T.1598SAAKPGAPRPPVPPKPGAPKPPVQPPKKPA1627 58 4.50E-06
N-terminal semi-tryptic peptides
2 S1 F.165GGFGLSGAAPQQWNEVKNKVPVEVAQDPSNPYR197.F 39 2.10E-03
S2 G.166GFGLSGAAPQQWNEVKNKVPVEVAQDPSNPYR197.F 34 3.20E-03
S3 F.168GLSGAAPQQWNEVKNKVPVEVAQDPSNPYR197.F 42 0.037
S4 G.169LSGAAPQQWNEVKNKVPVEVAQDPSNPYR197.F 59 5.00E-06
S5 S.171GAAPQQWNEVKNKVPVEVAQDPSNPYR197.F 46 3.0E-04
4 S6 D.248TAKSNEKLQGAEATGSSTTSGSGQSTQR275.G 126 1.00E-11
S7 A.250AKSNEKLQGAEATGSSTTSGSGQSTQR275.G 80 4.20E-07
5 S8 D.396PKAMTANYPPSWR408.T 103 1.40E-08
7 S9 D.684KNGKDDAKYIYPYR694.Y 58 1.90E-04
S10 N.686GKDDAKYIYPYR694.Y 61 2.00E-04
12 S11 L.1153IWAPRPWAAFR1163.G 56 2.00E-04
S12 I.1156WAPRPWAAFR1163.G 46 3.90E-03
S13 W.1154APRPWAAFR1163.G 49 3.30E-04
S14 A.1155PRPWAAFR1163.G 46 3.10E-03
14 S15 S.1344DGNTSSTNNLAPNTNTGNDVVGVGR1368.L 90 1.20E-08
S16 D.1345GNTSSTNNLAPNTNTGNDVVGVGR1368.L 192 8.00E-17
S17 G.1346NTSSTNNLAPNTNTGNDVVGVGR1368.L 158 1.20E-13
S18 N.1347TSSTNNLAPNTNTGNDVVGVGR1368.L 154 6.00E-13
S19 T.1348SSTNNLAPNTNTGNDVVGVGR1368.L 121 7.90E-10
S20 S.1349STNNLAPNTNTGNDVVGVGR1368.L 126 1.90E-10
S21 S.1350TNNLAPNTNTGNDVVGVGR1368.L 121 4.60E-11
S22 T.1351NNLAPNTNTGNDVVGVGR1368.L 117 4.20E-10
S23 N.1352NLAPNTNTGNDVVGVGR1368.L 132 1.00E-11
S24 N.1353LAPNTNTGNDVVGVGR1368.L 118 6.30E-10
S25 L.1354APNTNTGNDVVGVGR1368.L 104 4.00E-09
S26 A.1355PNTNTGNDVVGVGR1368.L 108 9.70E-10
S27 P.1356NTNTGNDVVGVGR1368.L 74 9.20E-06
S28 N.1357TNTGNDVVGVGR1368.L 85 3.40E-06
S29 T.1358NTGNDVVGVGR1368.L 80 1.90E-06
S30 N.1359TGNDVVGVGR1368.L 59 3.00E-04
S31 T.1360GNDVVGVGR1368.L 46 2.10E-03
S32 G.1361NDVVGVGR1368.L 52 4.40E-03
15 S33 D.1447IPASVNPKMVR1457.L 62 2.80E-05
C-terminal semi-tryptic peptides
2 R.137ALYDLDFSKLNPQTPTRDQTGQITFNPFG165.G 35 0.001
4 R.224TESGQNTSTTGAMFGLKVKNAEAD247.T 102 3.70E-09
Continued
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No. ID Peptide Sequence Score E-value
5 R.386TAIDRVDHLD395.P 38 6.40E-03
9 R.224NDKASSGQSDENHTKFTSATGMDQQGQSGTSAGNPDSLKQDNISKSG246.D 57 1.10E-05
R.224NDKASSGQSDENHTKFTSATGMDQQGQSGTSAGNPDSLKQDNISKSGD247.S 68 3.50E-06
13 R.1273QSFGTDHSTQPQPQSLKTTTPVFGTSSG1300.N 27 6.20E-03
Table 1. N-terminal dimethylated peptides identified in P1 adhesin by LC-MS/MS. Exact site within the 
peptide is indicated by the bold underlined amino acid. Amino acid positions denote the start and end of the 
peptides. The peptides listed are the highest scores identified from 4 biological replicates analysed separately 
using Sciex 5600 and Thermo Scientific Q Exactive™ mass spectrometers. All peptides have expectation values 
<0.05.
Figure 2. Immunoblots of cell lysates of M. pneumoniae probed with sera raised against regions within P1. 
Sera raised against 15 different regions (‘RP’ boxes) of P1 were a gift from R. Dumke55. (Top panel) Simplified 
cleavage map depicting the P1 adhesin, cleavage sites, and the 15 regions of P1 that have been previously 
cloned and expressed as recombinant fragments in E. coli55. The mass of full length and smaller proteoforms 
of P1 as predicted by ProtParam65. (Bottom panel) Immunoblots depicting M. pneumoniae cell lysate 
probed with the panel of anti-recombinant P1 sera. All the immunoblot lanes are part of the same blot. The 
membrane was blocked and then sliced to separate lanes before incubating with the described P1 sera. (Bottom 
right) Immunoblots with the intensity adjusted to highlight low abundant bands. Proteins migrating with 
masses similar to P1 proteoforms identified by LC-MS/MS have been marked on the immunoblot.
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of P1 represents a fifth site for high amino-peptidase activity with 18 neo-N-termini residing between amino acid 
positions 1343 – 1361 (cleavage site 14 in Table 1; sequence: 1341STS↓D↓G↓N↓T↓S↓S↓T↓N↓N↓L↓A↓P↓N↓T↓N
↓T↓G↓NDV1363).
Immunoblots of M. pneumoniae cell lysates probed individually with sera raised against the 15 recombinant 
regions spanning P155 showed complex banding profiles (Fig. 2). RP1 antiserum that targeted the signal sequence 
(first 59 amino acids) failed to identify P1 proteoforms suggesting that the signal peptide is destroyed during 
the early stages of processing of P1 and was also used as a secondary negative control (Fig. 2B). RP3, RP4, RP5, 
and RP7 span the first half of P1 and the immunoblots detected the full length protein and proteoforms consist-
ent with those representing P1 fragments 1, 2, 5, 7, 10, 13, 21, and 22 (Fig. 2B). P1 fragment 5 was identified in 
great abundance in RP4 sera, but no band was detected in RP3 or RP5. This could possibly be due to changes to 
exposed epitopes created from cleavage76–78, though further investigation is required. RP2, RP5, RP7 (higher 
antibody concentration), RP10, and RP14 sera revealed the full length adhesin and P1 fragments 1, 3, 4, 6, 8, 9, 11, 
12, 13, 14, 15, 18, 21, and 22 (Fig. 2C). Fragments of P1 that were not identified with confidence were 16, 17, 19, 
and 20. Data presented in Fig. 2B,C suggest that processing of P1 is complex.
Functional analysis of the C-terminal tail of P1. Dimethyl labelling data indicated that the 
carboxy-terminal 30 residues of P1 is released by a cleavage event at serine1598 (cleavage site 17 in Table 1, 
sequence: 1595KQT↓SAA1600). The C-terminal peptide has a composition comprising five alanine, five 
lysine, and thirteen proline residues. This C-terminal region also shares sequence identity (53.1%) with the 
carboxy-terminal 31 residues of Mpn142. Furthermore, the final 15 residues of P1 shares 73.3% sequence iden-
tity with the last 14 residues of Mpn142 (11 identical positions). The C-terminal 30 amino acids (named P1-30: 
1597TSAAKPGAPRPPVPPKPGAPKPPVQPPKKPA1627), and the C-terminal 15 amino acids (named P1-15 
1613PGAPKPPVQPPKKPA1627) were synthesised chemically (Table 2; Chempeptide Limited, China) and an 
N-terminal biotin tag was added to the P1-15 peptide. Microtitre binding assays revealed that P1-15, P1-30, 
and the recombinant protein, RP1555, bind a range of host molecules in a dose dependent manner (Fig. 3). M. 
pneumoniae cells and RP15 bound lactoferrin, vitronectin, plasminogen, fibronectin, and fibrinogen. Only M. 
pneumoniae cells bound laminin. P1-30 bound fibronectin, fibrinogen and plasminogen in a dose dependent 
manner but failed to bind laminin. P1-15 only bound plasminogen in a dose dependent manner but also bound 
to vitronectin but failed to bind laminin, lactoferrin, fibronectin, and fibrinogen (Fig. 3). Compared with P1-30 
and P1-15, the C-terminal 106 amino acids of P1 represented by RP15 consistently showed the most consistent 
and most diverse binding capabilities for the panel of host proteins tested here suggesting that multiple binding 
domains increase the binding capabilities of P1 proteoforms. Consistent with this hypothesis, RP15 spans two 
putative glycosaminoglycan binding motifs (underlined motifs in Table 2) that are absent in P1-30 and P1-15.
To investigate whether binding was due to the specific amino acid sequence or to amino acid com-
position, microscale thermophoresis was performed on P1-30 and a scrambled version of P1-30 
(PKPPRAAPPKAPTPVPPGPASPVKKPKQAPG). P1-30 had a medium binding affinity for plasminogen 
(KD = 554 ± 2.1 nM) and a medium/low binding affinity for fetuin (KD = 2.4 ± 0.7 μM). No binding affinity could 
be detected for the scrambled peptide (Fig. 4).
Microtitre binding assays were also employed to determine the binding capabilities of regions spanning the 
C-terminus of P1 to A549 human epithelial cells (Fig. 5). Recombinant pyruvate dehydrogenase subunit B of M. 
pneumoniae (rPdhB; positive control16) and RP15 bound immobilised A549 cells, but not P1-30. We were not able 
to determine if P1-15 bound using this assay because we lacked reagents that could detect this peptide.
To overcome this experimental limitation and to attempt to identify potential binding partners for P1-15, we 
designed an affinity bait-prey experiment. The biotinylated P1-15 was coupled to avidin agarose and, in paral-
lel with uncoupled avidin-agarose (negative control), were exposed to a native A549 cell lysate as described in 
Methods, washed and eluants were characterised by SDS-PAGE and LC-MS/MS (Fig. S1). Three protein bands 
identified in eluents from avidin-agarose coupled with biotinylated P1-15 that were absent in the control were 
analysed by LC-MS/MS (Fig. S1). LC-MS/MS analysis of slice 1 and 2 identified tryptic peptides that mapped to 
the intermediate filament cytoskeletal proteins cytokeratin 7 (Mascot score = 1157), cytokeratin 8 (Mascot score 
= 2737 & 1486), cytokeratin 18 (Mascot score = 2592), and vimentin (Mascot score = 617) (Fig. S1). Tryptic pep-
tides to these filament proteins were not identified in the control experiment. Tryptic peptides identified in slice 
3 identified glyceraldehyde-3-phosphate dehydrogenase, however, this protein was also identified in the eluents 
from the control and was not considered further as a potential binding partner with P1-15.
Discussion
M. pneumoniae binds diverse host cell proteins including plasminogen, fibronectin, vitronectin, fibrinogen, lacto-
ferrin, glycosaminoglycans, and sialoglyconjugates9–17.
The P1 adhesin and proteins it associates with at the tip of the attachment organelle are central to binding 
interactions that enable M. pneumoniae to target host cell receptors and is likely to contain binding domains 
Name Sequence Source
P1-15 1613PGAPKPPVQPPKKPA1627 This study





Table 2. The C-terminal fragments used in this study.
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for some or all of these host molecules. Here we show that Mpn141 is processed extensively generating 23 pro-
teoforms and that many proteoforms are retained on affinity matrices loaded with different host molecules and 
mimics of regions of host proteins including fetuin, fibronectin, actin, heparin, and plasminogen. Microtitre 
plate binding assays and microscale thermophoresis assays confirmed several of these preliminary findings and 
showed that the C-terminal region of P1 binds vitronectin, fibrinogen and fibronectin. Apart from removal of a 
59 amino acid N-terminal leader peptide, only a ~40 kDa carboxyl terminal truncated fragment of P1 (potentially 
representing fragment 18 from this study), that forms a complex with full length P1 protein, and other accessory 
proteins has been reported previously33 but earlier immunoblotting studies with anti-P1 monospecific antisera 
identified numerous smaller proteoforms of P1 that were not characterised2. Dimethyl labelling experiments 
enabled us to map the precise location of cleavage events in P1 (Table 1). P1 proteoforms are likely generated by 
proteases on the cell surface of M. pneumoniae or associated with the protein translocation machinery but their 
identities have not been confirmed. Biotinylation studies identified 13 proteoforms of P1 that were accessible 
on the surface of M. pneumoniae and our surface labelling and trypsin shaving experiments indicate that the 
Figure 3. Concentration-dependent binding of the C-terminus of P1 to different human proteins. Microtitre 
plate binding assays were used to measure the binding abilities of RP15, P1-30, and P1-15 to human 
plasminogen and to different components of the human extracellular matrix. Bovine serum albumin (BSA) and 
whole cell lysate proteins of M. pneumoniae (Mpn) were used as a negative and positive control, respectively. 
Results are shown from a single experiment with a mean and standard deviation of eight replicates. The 
experiment was independently repeated twice.
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proteoforms remain attached to the extracellular side of M. pneumoniae cell membranes. Our data is consistent 
with electron micrographs of M. pneumoniae immunostained with ferretin-labelled anti-P1 antibodies that depict 
gold particles at: i) the tip of the attachment organelle; ii) along the shaft of this structure; iii) at sites along the 
cell body; and iv) at sites distant from the M. pneumoniae membrane2. It is not known if some proteoforms are 
excreted into the extracellular milieu but it is conceivable that processing of P1 occurs after translocation and the 
fragments may remain anchored to the surface via the predicted C-terminal transmembrane domain similarly 
seen in P40 and P90 of M. pneumoniae27. Consistent with this view, we were unable to find tryptic peptides that 
mapped to the putative leader peptide residing in the N-terminus of P1 or in the bioinformatically predicted 
transmembrane domains, or the well characterised C-terminal transmembrane domain. However, we did find 
tryptic peptides in the bioinformatically predicted  transmembrane domain located around residue 1294.
Regions in P1 have been extensively characterised in an earlier study55. Highly immunogenic regions and 
adherence mediating regions were found distributed throughout P1 particularly in the carboxy-terminal half of 
the molecule55. Sera from patients infected with M. pneumoniae bound to regions in P1 that were not responsible 
for adherence55. It is conceivable that P1-derived proteoforms divert the binding of host antibodies away from 
regions in P1 required for adherence. We hypothesise that post-translational processing events release a pro-
portion of P1-derived proteoforms into the extracellular milieu, a process that may represent an immune decoy 
mechanism that seeks to bind and direct host antibodies away from M. pneumoniae. A similar scenario has been 
hypothesized for Protein M of Mycoplasma genitalium; a close relative of M. pneumoniae79.
Figure 4. Plasminogen and fetuin binding by P1-30 using microscale thermophoresis. Left: Thermophoretic 
output representing P1-30 (triangles) binding to plasminogen with a KD of 554 nM. A scrambled version of 
P1-30 (circles) could not be assigned a KD value. Right: Thermophoretic output representing P1-30 binding to 
fetuin with a KD of 2 μM. The scrambled peptide could not be assigned a KD value.
Figure 5. Binding of the C-terminus of P1 to immobilized A549 cells. Proteins, peptides, or A549 cells were 
immobilised in wells of a 96-well plate and binding was measured in a microtitre plate binding assay. ‘Without 
A549’ cells: protein and peptides were immobilised and detected by corresponding antisera (peptides with 
anti-RP15). ‘With A549 cells’: A549 cells were immobilised first before incubating with proteins and peptides. 
Whole antigen of M. pneumoniae (Mpn), recombinant PdhB, and RP8 served as positive and negative controls, 
respectively17. Bars represent mean and standard deviation of eight replicates from a single experiment. The 
experiment was independently repeated twice.
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Our affinity studies suggest that the different proteoforms retain the ability to bind to different host proteins, 
glycosaminoglycans and sialoglyconjugates. RP15 was observed to bind immobilised A549 cells in microtitre 
plate assays (Fig. 4). This was surprising as no adherence regions have been previously identified within RP15. 
Anti-RP15 antibodies were reported to be unable to inhibit M. pneumoniae adherence to primary human bron-
chial epithelial (HBEC) cells, human fetal lung fibroblasts (MRC-5), and human cervical carcinoma cells (HeLa)55 
suggesting that RP15 may bind to specific receptors only present on the A549 cell surface. We were unable to 
determine binding activity to A549 cells for P1-30 or P1-15 (Fig. 4) because anti-RP-15 antibodies did not detect 
these peptides. To investigate the binding capabilities of the C-terminal peptide P1-15, it was bound to avidin 
agarose and incubated with A549 cell lysates. This strategy selectively recovered cytoskeletal proteins, vimentin, 
cytokeratin 7, cytokeratin 8, and cytokeratin 18 (Fig. S1) from P1-15-avidin agarose but not from avidin agarose 
control experiments. Although preliminary, these observations are worthy of further study. Cytokeratin 7 is found 
in epithelia of lungs and other tissues80, and has been shown to be involved in stabilising cytokeratin 1881. Both 
cytokeratin 8 and 18 are major structural proteins of epithelial cells82 and are found in the intermediate filaments 
of A549 cells83. Cytokeratin 8 has been identified to reside on the cellular surface of carcinogenic keratinocyte 
cells (HaCat)84, carcinogenic mammary cells85, and carcinogenic hepatocytes86 suggesting they may be surface 
accessible on many cells. Cytokeratin 8 and 18 are co-expressed and frequently found associated together87,88. 
Vimentin forms filaments and is primarily expressed when epithelial cells transition into mesenchymal cells and 
function to induce changes in cell shape, motility and adhesin during this transition89,90. Vimentin has also been 
observed to be secreted to the extracellular matrix and on the surface of activated macrophages91. Cytokeratin 8, 
18, and vimentin are suggested to be targeted by different pathogens after successfully invading host cells84,92–95 or 
after inducing cytoskeletal rearrangement96–100. Pathogenic bacteria are known to interact with these cytoskeletal 
proteins during infection95,101,102. Although mycoplasma have long been considered to be cell surface-associated 
parasitic bacteria, this dogma has been challenged with numerous reports citing phylogenetically-divergent 
mycoplasmas residing within eukaryote cells and possessing the molecular machinery for selective uptake into, 
survival within, and release from phagosomes103–109.
We recently showed that Mpn142, a member of the same operon that houses the P1 gene (mpn141), and 
the surface accessible moonlighting adhesin, elongation factor Tu (Ef-Tu), are cleaved extensively12,28. 
Post-translational processing of adhesins has been well characterised in M. hyopneumoniae where cleavage frag-
ments have been shown to adhere to porcine cilia, porcine kidney epithelial cells, and a range of host molecules 
such as the glycosaminoglycan mimic heparin59–62,64,72,74,110–115, plasminogen60,112–114, actin116, and fibronec-
tin59,72,112–114. Processing of adhesin molecules is not confined to M. hyopneumoniae but has been described in 
Mycoplasma gallisepticum117, Mycoplasma fermentans118–120, M. genitalium121, and Spiroplasma citri122. Here we 
show that major adhesion molecules in M. pneumoniae, a phylogenetically distinct human pathogen, are pro-
cessed12,28. All these studies suggest that the processing of surface accessible proteins is widespread in Mollicutes. 
It is notable that all the P1 fragments that were recovered during heparin affinity chromatography contained puta-
tive glycosaminoglycan binding motifs except an N-terminal and a central fragment (Fig. 1, fragments 14 and 16). 
These motifs consist of clustered, positively charged amino acids that have been shown to have a role in binding 
to glycosaminoglycans69,72, actin123, and plasminogen123. Heparin mimics the glycosaminoglycans found in the 
extracellular matrix and on the surface of host cells124. M. hyopneumoniae, and M. gallisepticum have been shown 
to bind heparin to aid in host adherence110,125. Pathogens such as Staphylococcus and Neisseria spp., Helicobacter 
pylori, and Streptococcus pyogenes are able to recruit heparin to the bacterial cell surface and employ bound hep-
arin to bind other host molecules126. Finally, heparin has also been implicated in biofilm formation by increasing 
cell-cell interactions in the Gram-positive pathogens, S. aureus127 and Lactobacillus rhamnosus128. M. pneumoniae 
forms large, complex biofilms on abiotic surfaces34. Heparin affinity chromatography of M. pneumoniae has been 
performed previously129 identifying only nine proteins, none of which was P1. Recently, we showed that Ef-Tu 
in M. pneumoniae displays a strong affinity to heparin12. Collectively, our studies suggest that the ability to bind 
heparin is a universal strategy in microbial pathogenesis.
In several instances, we observed multiple cleavage sites within P1 that clustered within a defined region of 
P1. For example, 18 cleavage sites clustered between amino acids 1343–1361 in the C-terminus of P1 (Table 1). 
Sequential cleavage patterns similar to this was also reported in Mpn14228 and in Mhp493, a paralog of the major 
adhesin P97 (Mhp183) in M. hyopneumoniae74. Surfaceome studies of M. pneumoniae (data not shown) revealed 
the presence of surface accessible aminopeptidases that may target a neo-N-terminal cleavage event and sequen-
tially clip amino acids subsequent to the initial cleavage event. The function of these clipping events remains 
unknown but could be a mechanism to alter function and localisation of cleavage fragments, or represent a mech-
anism to recycle amino acids74. Cleavage site 14 in P1 (Fig. 1) occurs within a large predicted disordered region 
(amino acid range 1187–1382). The inherent flexibility of disordered regions make them accessible to protease 
activity130. Many major cleavage events identified in M. hyopneumoniae adhesin molecules reside with large dis-
ordered regions60–62,74,114,115.
The C-terminus of the P1 tail is homologous to the C-terminus of Mpn142 and the C-terminal 15 amino acids 
of P1 (1613PGAPKPPVQPPKKPA1627) has 73.3% sequence identity with the same region in Mpn142. Almost half 
of this sequence consists of proline residues while lysine is also heavily represented in this region. Proline-rich 
regions in proteins have been implicated in protein:protein interactions131–133 and it has been suggested that pro-
line residues could anchor the C-terminus of P1 in the cell membrane49. Lysine-rich regions are associated with 
binding plasminogen60,64,123,134,135, heparin59,61,69,72,115,136, actin116,123, and DNA75,137. While P1-15 and P1-30 bound 
plasminogen in a dose-responsive manner, it was notable that RP-15 bound it more strongly. RP-15 also bound 
fibronectin and fibrinogen more strongly than P1-30 (Fig. 3). These data suggest that extra binding sites for these 
host molecules are located upstream of the C-terminal 30 amino acids of P1. Previous work suggests that sialic 
acid is the dominant host receptor for the P1 adhesin18–21. Consistent with these earlier studies the P1 tail has 
a strong affinity to the sialic acid rich protein, fetuin. Our data indicates that the mature P1 proteoform and a 
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further nine smaller proteoforms of P1 bind fetuin. The ability to bind fetuin has been linked with biofilm forma-
tion in M. pneumoniae34.
conclusion
In summary, this study reports that the P1 adhesin is subject to extensive post-translational processing forming 
twenty-two proteoforms from seventeen cleavage sites. Each of the proteoforms retain the ability to bind to host 
molecules or their structural mimics and are surface accessible. Processing has been described in M. hyopneumo-
niae, M. gallisepticum, and S. citri and is likely to be a widespread mechanism to generate surface protein diversity 
and promote protein:protein interactions. Specifically we show that the C-terminus of P1 plays a role in adhering 
to a range of host molecules including cytoskeletal proteins. This study expands on our knowledge of the role that 
the P1 adhesin plays in interactions between M. pneumoniae and host cells.
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Data for this study is available on request from the corresponding author.
Received: 17 January 2019; Accepted: 20 March 2020;
Published: xx xx xxxx
References
 1. Krause, D. C. & Balish, M. F. Structure, function, and assembly of the terminal organelle of Mycoplasma pneumoniae. FEMS 
Microbiol Lett 198, 1–7 (2001).
 2. Baseman, J. B., Cole, R. M., Krause, D. C. & Leith, D. K. Molecular basis for cytadsorption of Mycoplasma pneumoniae. J Bacteriol 
151, 1514–1522 (1982).
 3. Feldner, J., Gobel, U. & Bredt, W. Mycoplasma pneumoniae adhesin localized to tip structure by monoclonal antibody. Nature 298, 
765–767 (1982).
 4. Krause, D. C. Mycoplasma pneumoniae cytadherence: unravelling the tie that binds. Mol Microbiol 20, 247–253 (1996).
 5. Seto, S., Layh-Schmitt, G., Kenri, T. & Miyata, M. Visualization of the attachment organelle and cytadherence proteins of 
Mycoplasma pneumoniae by immunofluorescence microscopy. J Bacteriol 183, 1621–1630, https://doi.org/10.1128/JB.183.5.1621-
1630.2001 (2001).
 6. Seto, S. & Miyata, M. Attachment organelle formation represented by localization of cytadherence proteins and formation of the 
electron-dense core in wild-type and mutant strains of Mycoplasma pneumoniae. J Bacteriol 185, 1082–1091 (2003).
 7. Nakane, D., Kenri, T., Matsuo, L. & Miyata, M. Systematic Structural Analyses of Attachment Organelle in Mycoplasma 
pneumoniae. PLoS Pathog 11, e1005299, https://doi.org/10.1371/journal.ppat.1005299 (2015).
 8. Baseman, J. B. et al. Identification of a 32-kilodalton protein of Mycoplasma pneumoniae associated with hemadsorption. Isr J Med 
Sci 23, 474–479 (1987).
 9. Dallo, S. F., Kannan, T. R., Blaylock, M. W. & Baseman, J. B. Elongation factor Tu and E1 beta subunit of pyruvate dehydrogenase 
complex act as fibronectin binding proteins in Mycoplasma pneumoniae. Mol Microbiol 46, 1041–1051 (2002).
 10. Gründel, A., Jacobs, E. & Dumke, R. Interactions of surface-displayed glycolytic enzymes of Mycoplasma pneumoniae with 
components of the human extracellular matrix. Int J Med Microbiol, https://doi.org/10.1016/j.ijmm.2016.09.001 (2016).
 11. Hagemann, L., Gründel, A., Jacobs, E. & Dumke, R. The surface-displayed chaperones GroEL and DnaK of Mycoplasma 
pneumoniae interact with human plasminogen and components of the extracellular matrix. Pathog Dis, https://doi.org/10.1093/
femspd/ftx017 (2017).
 12. Widjaja, M. et al. Elongation factor Tu is a multifunctional and processed moonlighting protein. Sci Rep 7, 11227, https://doi.
org/10.1038/s41598-017-10644-z (2017).
 13. Grimmer, J. & Dumke, R. Organization of multi-binding to host proteins: The glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) of Mycoplasma pneumoniae. Microbiol Res 218, 22–31, https://doi.org/10.1016/j.micres.2018.09.006 (2019).
 14. Dumke, R., Hausner, M. & Jacobs, E. Role of Mycoplasma pneumoniae glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in 
mediating interactions with the human extracellular matrix. Microbiology 157, 2328–2338, https://doi.org/10.1099/mic.0.048298-
0 (2011).
 15. Thomas, C., Jacobs, E. & Dumke, R. Characterization of pyruvate dehydrogenase subunit B and enolase as plasminogen-binding 
proteins in Mycoplasma pneumoniae. Microbiology 159, 352–365, https://doi.org/10.1099/mic.0.061184-0 (2013).
 16. Gründel, A., Friedrich, K., Pfeiffer, M., Jacobs, E. & Dumke, R. Subunits of the Pyruvate Dehydrogenase Cluster of Mycoplasma 
pneumoniae Are Surface-Displayed Proteins that Bind and Activate Human Plasminogen. PLoS One 10, e0126600, https://doi.
org/10.1371/journal.pone.0126600 (2015).
 17. Gründel, A., Pfeiffer, M., Jacobs, E. & Dumke, R. Network of Surface-Displayed Glycolytic Enzymes in Mycoplasma pneumoniae 
and Their Interactions with Human Plasminogen. Infect Immun 84, 666–676, https://doi.org/10.1128/IAI.01071-15 (2016).
 18. Kahane, I., Banai, M., Razin, S. & Feldner, J. Attachment of mycoplasmas to host cell membranes. Rev Infect Dis 4(Suppl), S185–192 
(1982).
 19. Loomes, L. M. et al. Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type. Nature 
307, 560–563 (1984).
 20. Loomes, L. M., Uemura, K. & Feizi, T. Interaction of Mycoplasma pneumoniae with erythrocyte glycolipids of I and i antigen types. 
Infect Immun 47, 15–20 (1985).
 21. Roberts, D. D., Olson, L. D., Barile, M. F., Ginsburg, V. & Krivan, H. C. Sialic acid-dependent adhesion of Mycoplasma pneumoniae 
to purified glycoproteins. J Biol Chem 264, 9289–9293 (1989).
 22. Inamine, J. M., Loechel, S. & Hu, P. C. Analysis of the nucleotide sequence of the P1 operon of Mycoplasma pneumoniae. Gene 73, 
175–183 (1988).
 23. Waldo, R. H. III. & Krause, D. C. Synthesis, stability, and function of cytadhesin P1 and accessory protein B/C complex of 
Mycoplasma pneumoniae. J Bacteriol 188, 569–575, https://doi.org/10.1128/JB.188.2.569-575.2006 (2006).
 24. Aravind, L. & Koonin, E. V. A novel family of predicted phosphoesterases includes Drosophila prune protein and bacterial RecJ 
exonuclease. Trends Biochem Sci 23, 17–19 (1998).
 25. Postic, G., Danchin, A. & Mechold, U. Characterization of NrnA homologs from Mycobacterium tuberculosis and Mycoplasma 
pneumoniae. RNA 18, 155–165, https://doi.org/10.1261/rna.029132.111 (2012).
 26. Sperker, B., Hu, P. & Herrmann, R. Identification of gene products of the P1 operon of Mycoplasma pneumoniae. Mol Microbiol 5, 
299–306 (1991).
 27. Layh-Schmitt, G. & Herrmann, R. Localization and biochemical characterization of the ORF6 gene product of the Mycoplasma 
pneumoniae P1 operon. Infect Immun 60, 2906–2913 (1992).
13Scientific RepoRtS |         (2020) 10:6384  | https://doi.org/10.1038/s41598-020-63136-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
 28. Widjaja, M., Berry, I. J., Pont, E. J., Padula, M. P. & Djordjevic, S. P. P40 and P90 from Mpn142 are Targets of Multiple Processing 
Events on the Surface of Mycoplasma pneumoniae. Proteomes 3, 512–537, https://doi.org/10.3390/proteomes3040512 (2015).
 29. Inamine, J. M. et al. Nucleotide sequence of the P1 attachment-protein gene of Mycoplasma pneumoniae. Gene 64, 217–229 (1988).
 30. Layh-Schmitt, G. & Herrmann, R. Spatial arrangement of gene products of the P1 operon in the membrane of Mycoplasma 
pneumoniae. Infect Immun 62, 974–979 (1994).
 31. Franzoso, G., Hu, P. C., Meloni, G. A. & Barile, M. F. The immunodominant 90-kilodalton protein is localized on the terminal tip 
structure of Mycoplasma pneumoniae. Infect Immun 61, 1523–1530 (1993).
 32. Nakane, D., Adan-Kubo, J., Kenri, T. & Miyata, M. Isolation and characterization of P1 adhesin, a leg protein of the gliding 
bacterium Mycoplasma pneumoniae. J Bacteriol 193, 715–722, https://doi.org/10.1128/JB.00796-10 (2011).
 33. Layh-Schmitt, G., Podtelejnikov, A. & Mann, M. Proteins complexed to the P1 adhesin of Mycoplasma pneumoniae. Microbiology 
146(Pt 3), 741–747 (2000).
 34. Kornspan, J. D., Tarshis, M. & Rottem, S. Adhesion and biofilm formation of Mycoplasma pneumoniae on an abiotic surface. Arch 
Microbiol 193, 833–836, https://doi.org/10.1007/s00203-011-0749-y (2011).
 35. Hu, P. C. et al. Mycoplasma pneumoniae infection: role of a surface protein in the attachment organelle. Science 216, 313–315 
(1982).
 36. Razin, S. & Jacobs, E. Mycoplasma adhesion. J Gen Microbiol 138, 407–422, https://doi.org/10.1099/00221287-138-3-407 (1992).
 37. Svenstrup, H. F., Nielsen, P. K., Drasbek, M., Birkelund, S. & Christiansen, G. Adhesion and inhibition assay of Mycoplasma 
genitalium and M. pneumoniae by immunofluorescence microscopy. J Med Microbiol 51, 361–373, https://doi.org/10.1099/0022-
1317-51-5-361 (2002).
 38. Seto, S., Kenri, T., Tomiyama, T. & Miyata, M. Involvement of P1 adhesin in gliding motility of Mycoplasma pneumoniae as 
revealed by the inhibitory effects of antibody under optimized gliding conditions. J Bacteriol 187, 1875–1877, https://doi.
org/10.1128/JB.187.5.1875-1877.2005 (2005).
 39. Hu, P. C., Collier, A. M. & Baseman, J. B. Surface parasitism by Mycoplasma pneumoniae of respiratory epithelium. J Exp Med 145, 
1328–1343 (1977).
 40. Kahane, I., Tucker, S., Leith, D. K., Morrison-Plummer, J. & Baseman, J. B. Detection of the major adhesin P1 in triton shells of 
virulent Mycoplasma pneumoniae. Infect Immun 50, 944–946 (1985).
 41. Morrison-Plummer, J., Leith, D. K. & Baseman, J. B. Biological effects of anti-lipid and anti-protein monoclonal antibodies on 
Mycoplasma pneumoniae. Infect Immun 53, 398–403 (1986).
 42. Krause, D. C. & Balish, M. F. Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of 
Mycoplasma pneumoniae. Mol Microbiol 51, 917–924 (2004).
 43. Layh-Schmitt, G. & Harkenthal, M. The 40- and 90-kDa membrane proteins (ORF6 gene product) of Mycoplasma pneumoniae are 
responsible for the tip structure formation and P1 (adhesin) association with the Triton shell. FEMS Microbiol Lett 174, 143–149 
(1999).
 44. Waldo, R. H. III., Jordan, J. L. & Krause, D. C. Identification and complementation of a mutation associated with loss of 
Mycoplasma pneumoniae virulence-specific proteins B and C. J Bacteriol 187, 747–751, https://doi.org/10.1128/JB.187.2.747-
751.2005 (2005).
 45. Hahn, T. W., Willby, M. J. & Krause, D. C. HMW1 is required for cytadhesin P1 trafficking to the attachment organelle in 
Mycoplasma pneumoniae. J Bacteriol 180, 1270–1276 (1998).
 46. Cloward, J. M. & Krause, D. C. Loss of co-chaperone TopJ impacts adhesin P1 presentation and terminal organelle maturation in 
Mycoplasma pneumoniae. Mol Microbiol 81, 528–539, https://doi.org/10.1111/j.1365-2958.2011.07712.x (2011).
 47. Hirschberg, L., Holme, T. & Krook, A. Human antibody response to the major adhesin of Mycoplasma pneumoniae: increase in 
titers against synthetic peptides in patients with pneumonia. APMIS 99, 515–520 (1991).
 48. Tuuminen, T., Suni, J., Kleemola, M. & Jacobs, E. Improved sensitivity and specificity of enzyme immunoassays with P1-adhesin 
enriched antigen to detect acute Mycoplasma pneumoniae infection. J Microbiol Methods 44, 27–37 (2001).
 49. Dallo, S. F., Su, C. J., Horton, J. R. & Baseman, J. B. Identification of P1 gene domain containing epitope(s) mediating Mycoplasma 
pneumoniae cytoadherence. J Exp Med 167, 718–723 (1988).
 50. Gerstenecker, B. & Jacobs, E. Topological mapping of the P1-adhesin of Mycoplasma pneumoniae with adherence-inhibiting 
monoclonal antibodies. J Gen Microbiol 136, 471–476, https://doi.org/10.1099/00221287-136-3-471 (1990).
 51. Jacobs, E., Bartl, A., Oberle, K. & Schiltz, E. Molecular mimicry by Mycoplasma pneumoniae to evade the induction of adherence 
inhibiting antibodies. J Med Microbiol 43, 422–429, https://doi.org/10.1099/00222615-43-6-422 (1995).
 52. Chaudhry, R., Nisar, N., Hora, B., Chirasani, S. R. & Malhotra, P. Expression and immunological characterization of the carboxy-
terminal region of the P1 adhesin protein of Mycoplasma pneumoniae. J Clin Microbiol 43, 321–325, https://doi.org/10.1128/
JCM.43.1.321-325.2005 (2005).
 53. Drasbek, M., Christiansen, G., Drasbek, K. R., Holm, A. & Birkelund, S. Interaction between the P1 protein of Mycoplasma 
pneumoniae and receptors on HEp-2 cells. Microbiology 153, 3791–3799, https://doi.org/10.1099/mic.0.2007/010736-0 (2007).
 54. Beghetto, E., De Paolis, F., Montagnani, F., Cellesi, C. & Gargano, N. Discovery of new Mycoplasma pneumoniae antigens by use 
of a whole-genome lambda display library. Microbes Infect 11, 66–73, https://doi.org/10.1016/j.micinf.2008.10.004 (2009).
 55. Schurwanz, N., Jacobs, E. & Dumke, R. Strategy to create chimeric proteins derived from functional adhesin regions of 
Mycoplasma pneumoniae for vaccine development. Infect Immun 77, 5007–5015, https://doi.org/10.1128/IAI.00268-09 (2009).
 56. Hausner, M., Schamberger, A., Naumann, W., Jacobs, E. & Dumke, R. Development of protective anti-Mycoplasma pneumoniae 
antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan. 
Microb Pathog 64, 23–32, https://doi.org/10.1016/j.micpath.2013.07.004 (2013).
 57. Berry, I. J. et al. N-terminomics identifies widespread endoproteolysis and novel methionine excision in a genome-reduced 
bacterial pathogen. Sci Rep 7, 11063, https://doi.org/10.1038/s41598-017-11296-9 (2017).
 58. Hayflick, L. Tissue cultures and mycoplasmas. Tex Rep Biol Med 23(Suppl 1), 285+ (1965).
 59. Deutscher, A. T. et al. Repeat regions R1 and R2 in the P97 paralogue Mhp271 of Mycoplasma hyopneumoniae bind heparin, 
fibronectin and porcine cilia. Mol Microbiol 78, 444–458, https://doi.org/10.1111/j.1365-2958.2010.07345.x (2010).
 60. Bogema, D. R. et al. Characterization of cleavage events in the multifunctional cilium adhesin Mhp684 (P146) reveals a mechanism 
by which Mycoplasma hyopneumoniae regulates surface topography. MBio 3, https://doi.org/10.1128/mBio.00282-11 (2012).
 61. Raymond, B. B. et al. P159 from Mycoplasma hyopneumoniae binds porcine cilia and heparin and is cleaved in a manner akin to 
ectodomain shedding. J Proteome Res 12, 5891–5903, https://doi.org/10.1021/pr400903s (2013).
 62. Bogema, D. R. et al. Sequence TTKF downward arrow QE defines the site of proteolytic cleavage in Mhp683 protein, a novel 
glycosaminoglycan and cilium adhesin of Mycoplasma hyopneumoniae. J Biol Chem 286, 41217–41229, https://doi.org/10.1074/
jbc.M111.226084 (2011).
 63. Webb, A. Systems Biology Mascot Server: Databases (MSPnr100), http://www.wehi.edu.au/people/andrew-webb/1295/andrew-
webb-resources (2015).
 64. Tacchi, J. L. et al. Post-translational processing targets functionally diverse proteins in Mycoplasma hyopneumoniae. Open Biol 6, 
150210, https://doi.org/10.1098/rsob.150210 (2016).
 65. Wilkins, M. R. et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112, 531–552 (1999).
 66. Hofmann, K. & TMbase, S. W. - A database of membrane spanning proteins segments. Biol. Chem. 374, 166 (1993).
1 4Scientific RepoRtS |         (2020) 10:6384  | https://doi.org/10.1038/s41598-020-63136-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
 67. Peng, K., Radivojac, P., Vucetic, S., Dunker, A. K. & Obradovic, Z. Length-dependent prediction of protein intrinsic disorder. BMC 
Bioinformatics 7, 208, https://doi.org/10.1186/1471-2105-7-208 (2006).
 68. de Castro, E. et al. ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues 
in proteins. Nucleic Acids Res 34, W362–365, https://doi.org/10.1093/nar/gkl124 (2006).
 69. Cardin, A. D. & Weintraub, H. J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21–32 (1989).
 70. Klimstra, W. B., Heidner, H. W. & Johnston, R. E. The furin protease cleavage recognition sequence of Sindbis virus PE2 can 
mediate virion attachment to cell surface heparan sulfate. J Virol 73, 6299–6306 (1999).
 71. Kyhse-Andersen, J. Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from 
polyacrylamide to nitrocellulose. J Biochem Biophys Methods 10, 203–209 (1984).
 72. Raymond, B. B. et al. Proteolytic processing of the cilium adhesin MHJ_0194 (P123J) in Mycoplasma hyopneumoniae generates a 
functionally diverse array of cleavage fragments that bind multiple host molecules. Cell Microbiol 17, 425–444, https://doi.
org/10.1111/cmi.12377 (2015).
 73. Aparicio, D. et al. Mycoplasma genitalium adhesin P110 binds sialic-acid human receptors. Nat Commun 9, 4471, https://doi.
org/10.1038/s41467-018-06963-y (2018).
 74. Tacchi, J. L. et al. Cilium adhesin P216 (MHJ_0493) is a target of ectodomain shedding and aminopeptidase activity on the surface 
of Mycoplasma hyopneumoniae. J Proteome Res 13, 2920–2930, https://doi.org/10.1021/pr500087c (2014).
 75. Jarocki, V. M. et al. MHJ_0461 is a multifunctional leucine aminopeptidase on the surface of Mycoplasma hyopneumoniae. Open 
Biol 5, 140175, https://doi.org/10.1098/rsob.140175 (2015).
 76. Hahm, K. S. et al. Limited proteolysis selectively destroys epitopes on apolipoprotein B in low density lipoproteins. J Lipid Res 24, 
877–885 (1983).
 77. Mayne, R. et al. Monoclonal antibody to the aminotelopeptide of type II collagen: loss of the epitope after stromelysin digestion. 
Connect Tissue Res 31, 11–21, https://doi.org/10.3109/03008209409005631 (1994).
 78. Ossendorp, F. et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack 
of antigen presentation. Immunity 5, 115–124, https://doi.org/10.1016/s1074-7613(00)80488-4 (1996).
 79. Grover, R. K. et al. A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. Science 343, 
656–661, https://doi.org/10.1126/science.1246135 (2014).
 80. van Niekerk, C. C., Jap, P. H., Ramaekers, F. C., van de Molengraft, F. & Poels, L. G. Immunohistochemical demonstration of keratin 
7 in routinely fixed paraffin-embedded human tissues. J Pathol 165, 145–152, https://doi.org/10.1002/path.1711650210 (1991).
 81. Sandilands, A. et al. Generation and characterisation of keratin 7 (K7) knockout mice. PLoS One 8, e64404, https://doi.org/10.1371/
journal.pone.0064404 (2013).
 82. Owens, D. W. & Lane, E. B. The quest for the function of simple epithelial keratins. Bioessays 25, 748–758, https://doi.org/10.1002/
bies.10316 (2003).
 83. Dobashi, N. et al. Detection of anti-cytokeratin 8 antibody in the serum of patients with cryptogenic fibrosing alveolitis and 
pulmonary fibrosis associated with collagen vascular disorders. Thorax 53, 969–974 (1998).
 84. Haim, M. et al. Cytokeratin 8 interacts with clumping factor B: a new possible virulence factor target. Microbiology 156, 3710–3721, 
https://doi.org/10.1099/mic.0.034413-0 (2010).
 85. Godfroid, E., Geuskens, M., Dupressoir, T., Parent, I. & Szpirer, C. Cytokeratins are exposed on the outer surface of established 
human mammary carcinoma cells. J Cell Sci 99(Pt 3), 595–607 (1991).
 86. Hembrough, T. A., Vasudevan, J., Allietta, M. M., Glass, W. F. 2nd & Gonias, S. L. A cytokeratin 8-like protein with plasminogen-
binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 108(Pt 3), 
1071–1082 (1995).
 87. Lu, X. & Lane, E. B. Retrovirus-mediated transgenic keratin expression in cultured fibroblasts: specific domain functions in keratin 
stabilization and filament formation. Cell 62, 681–696 (1990).
 88. Moll, R., Franke, W. W., Schiller, D. L., Geiger, B. & Krepler, R. The catalog of human cytokeratins: patterns of expression in normal 
epithelia, tumors and cultured cells. Cell 31, 11–24 (1982).
 89. Mendez, M. G., Kojima, S. & Goldman, R. D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial 
to mesenchymal transition. FASEB J 24, 1838–1851, https://doi.org/10.1096/fj.09-151639 (2010).
 90. Franke, W. W., Schiller, D. L., Hatzfeld, M. & Winter, S. Protein complexes of intermediate-sized filaments: melting of cytokeratin 
complexes in urea reveals different polypeptide separation characteristics. Proc Natl Acad Sci USA 80, 7113–7117 (1983).
 91. Mor-Vaknin, N., Punturieri, A., Sitwala, K. & Markovitz, D. M. Vimentin is secreted by activated macrophages. Nat Cell Biol 5, 
59–63, https://doi.org/10.1038/ncb898 (2003).
 92. Tamura, G. S. & Nittayajarn, A. Group B streptococci and other gram-positive cocci bind to cytokeratin 8. Infect Immun 68, 
2129–2134 (2000).
 93. Scherer, C. A., Cooper, E. & Miller, S. I. The Salmonella type III secretion translocon protein SspC is inserted into the epithelial cell 
plasma membrane upon infection. Mol Microbiol 37, 1133–1145 (2000).
 94. Carlson, S. A., Omary, M. B. & Jones, B. D. Identification of cytokeratins as accessory mediators of Salmonella entry into eukaryotic 
cells. Life Sci 70, 1415–1426 (2002).
 95. Mak, T. N. et al. Propionibacterium acnes host cell tropism contributes to vimentin-mediated invasion and induction of 
inflammation. Cell Microbiol 14, 1720–1733, https://doi.org/10.1111/j.1462-5822.2012.01833.x (2012).
 96. Batchelor, M. et al. Involvement of the intermediate filament protein cytokeratin-18 in actin pedestal formation during EPEC 
infection. EMBO Rep 5, 104–110, https://doi.org/10.1038/sj.embor.7400038 (2004).
 97. Viswanathan, V. K. et al. Cytokeratin 18 interacts with the enteropathogenic Escherichia coli secreted protein F (EspF) and is 
redistributed after infection. Cell Microbiol 6, 987–997, https://doi.org/10.1111/j.1462-5822.2004.00416.x (2004).
 98. Icenogle, L. M. et al. Molecular and biological characterization of Streptococcal SpyA-mediated ADP-ribosylation of intermediate 
filament protein vimentin. J Biol Chem 287, 21481–21491, https://doi.org/10.1074/jbc.M112.370791 (2012).
 99. Murli, S., Watson, R. O. & Galan, J. E. Role of tyrosine kinases and the tyrosine phosphatase SptP in the interaction of Salmonella 
with host cells. Cell Microbiol 3, 795–810 (2001).
 100. Guignot, J. & Servin, A. L. Maintenance of the Salmonella-containing vacuole in the juxtanuclear area: a role for intermediate 
filaments. Microb Pathog 45, 415–422, https://doi.org/10.1016/j.micpath.2008.09.007 (2008).
 101. Saberi, S. et al. A potential association between Helicobacter pylori CagA EPIYA and multimerization motifs with cytokeratin 18 
cleavage rate during early apoptosis. Helicobacter 17, 350–357, https://doi.org/10.1111/j.1523-5378.2012.00954.x (2012).
 102. Kumar, Y. & Valdivia, R. H. Actin and intermediate filaments stabilize the Chlamydia trachomatis vacuole by forming dynamic 
structural scaffolds. Cell Host Microbe 4, 159–169, https://doi.org/10.1016/j.chom.2008.05.018 (2008).
 103. Yavlovich, A., Tarshis, M. & Rottem, S. Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic 
cells. FEMS Microbiol Lett 233, 241–246, https://doi.org/10.1016/j.femsle.2004.02.016 (2004).
 104. Tsiodras, S., Kelesidis, I., Kelesidis, T., Stamboulis, E. & Giamarellou, H. Central nervous system manifestations of Mycoplasma 
pneumoniae infections. J Infect 51, 343–354, https://doi.org/10.1016/j.jinf.2005.07.005 (2005).
 105. Burki, S. et al. Invasion and persistence of Mycoplasma bovis in embryonic calf turbinate cells. Vet Res 46, 53, https://doi.
org/10.1186/s13567-015-0194-z (2015).
 106. Burki, S., Frey, J. & Pilo, P. Virulence, persistence and dissemination of Mycoplasma bovis. Vet Microbiol 179, 15–22, https://doi.
org/10.1016/j.vetmic.2015.02.024 (2015).
1 5Scientific RepoRtS |         (2020) 10:6384  | https://doi.org/10.1038/s41598-020-63136-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
 107. Suleman, M. et al. Mycoplasma bovis isolates recovered from cattle and bison (Bison bison) show differential in vitro effects on 
PBMC proliferation, alveolar macrophage apoptosis and invasion of epithelial and immune cells. Vet Microbiol 186, 28–36, https://
doi.org/10.1016/j.vetmic.2016.02.016 (2016).
 108. Josi, C. et al. Bovine Epithelial in vitro Infection Models for Mycoplasma bovis. Frontiers in cellular and infection microbiology 8, 
329, https://doi.org/10.3389/fcimb.2018.00329 (2018).
 109. Raymond, B. B. A. et al. Mycoplasma hyopneumoniae resides intracellularly within porcine epithelial cells. Sci Rep 8, 17697, 
https://doi.org/10.1038/s41598-018-36054-3 (2018).
 110. Burnett, T. A. et al. P159 is a proteolytically processed, surface adhesin of Mycoplasma hyopneumoniae: defined domains of P159 
bind  hep ar in  and  promote  ad herence  to  eu kar yote  ce l l s .  Mol  Microbiol  60 ,  669–686 ,  https : / /doi .
org/10.1111/j.1365-2958.2006.05139.x (2006).
 111. Wilton, J. et al. Mhp493 (P216) is a proteolytically processed, cilium and heparin binding protein of Mycoplasma hyopneumoniae. 
Mol Microbiol 71, 566–582, https://doi.org/10.1111/j.1365-2958.2008.06546.x (2009).
 112. Seymour, L. M. et al. A processed multidomain mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen, and swine 
respiratory cilia. J Biol Chem 285, 33971–33978, https://doi.org/10.1074/jbc.M110.104463 (2010).
 113. Seymour, L. M. et al. Mhp107 is a member of the multifunctional adhesin family of Mycoplasma hyopneumoniae. J Biol Chem 286, 
10097–10104, https://doi.org/10.1074/jbc.M110.208140 (2011).
 114. Seymour, L. M. et al. Mhp182 (P102) binds fibronectin and contributes to the recruitment of plasmin(ogen) to the Mycoplasma 
hyopneumoniae cell surface. Cell Microbiol 14, 81–94, https://doi.org/10.1111/j.1462-5822.2011.01702.x (2012).
 115. Deutscher, A. T. et al. Mycoplasma hyopneumoniae Surface proteins Mhp385 and Mhp384 bind host cilia and glycosaminoglycans 
and are endoproteolytically processed by proteases that recognize different cleavage motifs. J Proteome Res 11, 1924–1936, https://
doi.org/10.1021/pr201115v (2012).
 116. Raymond, B. B. A. et al. Extracellular Actin Is a Receptor for Mycoplasma hyopneumoniae. Frontiers in cellular and infection 
microbiology 8, 54, https://doi.org/10.3389/fcimb.2018.00054 (2018).
 117. Szczepanek, S. M. et al. Identification of lipoprotein MslA as a neoteric virulence factor of Mycoplasma gallisepticum. Infect Immun 
78, 3475–3483, https://doi.org/10.1128/IAI.00154-10 (2010).
 118. Calcutt, M. J., Kim, M. F., Karpas, A. B., Muhlradt, P. F. & Wise, K. S. Differential posttranslational processing confers intraspecies 
variation of a major surface lipoprotein and a macrophage-activating lipopeptide of Mycoplasma fermentans. Infect Immun 67, 
760–771 (1999).
 119. Davis, K. L. & Wise, K. S. Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective 
lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans. Infect 
Immun 70, 1129–1135 (2002).
 120. Muhlradt, P. F., Kiess, M., Meyer, H., Sussmuth, R. & Jung, G. Isolation, structure elucidation, and synthesis of a macrophage 
stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185, 1951–1958 (1997).
 121. Shimizu, T., Kida, Y. & Kuwano, K. A triacylated lipoprotein from Mycoplasma genitalium activates NF-kappaB through Toll-like 
receptor 1 (TLR1) and TLR2. Infect Immun 76, 3672–3678, https://doi.org/10.1128/IAI.00257-08 (2008).
 122. Dubrana, M. P. et al. Proteolytic post-translational processing of adhesins in the plant pathogen Spiroplasma citri. J Mol Biol 
https://doi.org/10.1016/j.jmb.2017.05.004 (2017).
 123. Boone, T. J. & Tyrrell, G. J. Identification of the actin and plasminogen binding regions of group B streptococcal phosphoglycerate 
kinase. J Biol Chem 287, 29035–29044, https://doi.org/10.1074/jbc.M112.361261 (2012).
 124. Kamhi, E., Joo, E. J., Dordick, J. S. & Linhardt, R. J. Glycosaminoglycans in infectious disease. Biol Rev Camb Philos Soc 88, 
928–943, https://doi.org/10.1111/brv.12034 (2013).
 125. Jenkins, C., Geary, S. J., Gladd, M. & Djordjevic, S. P. The Mycoplasma gallisepticum OsmC-like protein MG1142 resides on the 
cell surface and binds heparin. Microbiology 153, 1455–1463, https://doi.org/10.1099/mic.0.2006/004937-0 (2007).
 126. Duensing, T. D., Wing, J. S. & van Putten, J. P. Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel 
strategy in microbial pathogenesis. Infect Immun 67, 4463–4468 (1999).
 127. Shanks, R. M. et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 73, 4596–4606, https://doi.
org/10.1128/IAI.73.8.4596-4606.2005 (2005).
 128. Chen, X. E., Ling, P., Duan, R. & Zhang, T. Effects of heparosan and heparin on the adhesion and biofilm formation of several 
bacteria in vitro. Carbohydrate polymers 88, 1288–1292 (2012).
 129. Ueberle, B., Frank, R. & Herrmann, R. The proteome of the bacterium Mycoplasma pneumoniae: comparing predicted open 
reading frames to identified gene products. Proteomics 2, 754–764, 10.1002/1615-9861(200206)2:6<754::AID-
PROT754>3.0.CO;2-2 (2002).
 130. Uversky, V. N. & Dunker, A. K. Understanding protein non-folding. Biochim Biophys Acta 1804, 1231–1264, https://doi.
org/10.1016/j.bbapap.2010.01.017 (2010).
 131. Boguslavsky, S. et al. Molecular characterization of the Mycoplasma gallisepticum pvpA gene which encodes a putative variable 
cytadhesin protein. Infect Immun 68, 3956–3964 (2000).
 132. Williamson, M. P. The structure and function of proline-rich regions in proteins. Biochem J 297(Pt 2), 249–260 (1994).
 133. Kay, B. K., Williamson, M. P. & Sudol, M. The importance of being proline: the interaction of proline-rich motifs in signaling 
proteins with their cognate domains. FASEB J 14, 231–241 (2000).
 134. Cork, A. J. et al. Defining the structural basis of human plasminogen binding by streptococcal surface enolase. J Biol Chem 284, 
17129–17137, https://doi.org/10.1074/jbc.M109.004317 (2009).
 135. Raymond, B. B. & Djordjevic, S. Exploitation of plasmin(ogen) by bacterial pathogens of veterinary significance. Vet Microbiol 178, 
1–13, https://doi.org/10.1016/j.vetmic.2015.04.008 (2015).
 136. Robinson, M. W. et al. MHJ_0125 is an M42 glutamyl aminopeptidase that moonlights as a multifunctional adhesin on the surface 
of Mycoplasma hyopneumoniae. Open Biol 3, 130017, https://doi.org/10.1098/rsob.130017 (2013).
 137. Lee, A. Y., Hsu, C. H. & Wu, S. H. Functional domains of Brevibacillus thermoruber lon protease for oligomerization and DNA 
binding: role of N-terminal and sensor and substrate discrimination domains. J Biol Chem 279, 34903–34912, https://doi.
org/10.1074/jbc.M403562200 (2004).
Acknowledgements
This research is supported by an Australian Government Research Training Program Scholarship provided to 
I.J.B. The authors would like to thank Mark Raftery and the Bioanalytical Mass Spectrometry Facility (BMSF) 
for access to the Sciex 5600 and Thermo Scientific Q Exactive™ Plus mass spectrometers purchased with the 
ARC grant LE130100096 entitled ‘Advanced high resolution mass spectrometer for collaborative proteomic 
and lipidomics research’. The authors would like to thank both the University of Technology Sydney and the 
Technische Universität Dresden for funding this research.
1 6Scientific RepoRtS |         (2020) 10:6384  | https://doi.org/10.1038/s41598-020-63136-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author contributions
M.W. acquired and analysed the data except those listed for I.J.B., V.M.J. and R.D. Dimethyl labelling experiments 
was performed by I.J.B. Results from dimethyl labelling experiments was analysed by both M.W. and I.J.B. The 
experiments investigating the binding of the P1 C-terminus to human proteins and A549 human lung cells were 
conducted and analysed by R.D. Microscale thermophoresis of the scrambled P1 peptide was performed and data 
analysed by V.M.J. Acquisition of mass spectrometry data was performed by M.P.P. who also assisted with mass 
spectrometry data interpretation. R.D. created the figures for microtitre plate binding assays and all other figures 
were created by M.W. Both M.W. and S.P.D. wrote the manuscript. S.P.D. initiated the study. Both S.P.D. and R.D. 
secured funding for this study. The manuscript was reviewed and approved by all authors before submission.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63136-y.
Correspondence and requests for materials should be addressed to S.P.D.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
